Merck-Eisai's cancer drug combo meets one main goal in late-stage study-February 2024-www.financetom.com

Merck-Eisai's cancer drug combo meets one main goal in late-stage study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Merck-Eisai's cancer drug combo meets one main goal in late-stage study

Oct 28, 2025 3:53 AM

Oct 28 (Reuters) - Merck ( MRK ) and Eisai's ( ESALF )

experimental combination treatment for a type of kidney cancer

met one of the main goals in a late-stage study, the drugmakers

said on Tuesday.

Previous page： Bitdeer Technologies Group's Bitcoin Output Rises 21% in September Next page： Equity Bancshares Q3 Swings to Loss, Revenue Declines

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Bitdeer Technologies Group's Bitcoin Output Rises 21% in September

Oct 14, 2025

04:56 PM EDT, 10/14/2025 (MT Newswires) -- Bitdeer Technologies Group ( BTDR ) mined 452 bitcoins in September, up almost 21% from 375 in August. Cryptocurrency mining rigs under management rose to 241,000 in September from 229,000 in August, the company said Tuesday in a statement. Bitcoin holdings in September rose to 2,029 from 1,934 in August. The company received...

Equity Bancshares Q3 Swings to Loss, Revenue Declines

Oct 14, 2025

04:52 PM EDT, 10/14/2025 (MT Newswires) -- Equity Bancshares ( EQBK ) reported a Q3 loss late Tuesday of $1.55 per diluted share, swinging from earnings of $1.28 a year earlier. Two analysts polled by FactSet expected earnings $0.95 per share. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and noninterest income, was...

EyePoint Pharmaceuticals Initiates Phase 3 Program for Duravyu to Treat Diabetic Macular Edema

Oct 14, 2025

04:56 PM EDT, 10/14/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said Tuesday it is initiating its phase 3 program to evaluate Duravyu for the treatment of diabetic macular edema. First patient dosing is expected in Q1 2026, the company said. EyePoint said the phase 3 program will comprise two identical non-inferiority trials, with each trial to enroll about...

BRIEF-Civista Bancshares And The Farmers Savings Bank Announce Receipt Of Regulatory Approvals For Proposed Merger

Oct 14, 2025

Oct 14 (Reuters) - Civista Bancshares Inc ( CIVB ): * CIVISTA BANCSHARES, INC. ( CIVB ) AND THE FARMERS SAVINGS BANK ANNOUNCE RECEIPT OF REGULATORY APPROVALS FOR PROPOSED MERGER * CIVISTA BANCSHARES INC ( CIVB ): PARTIES INTEND TO CLOSE TRANSACTION IN NOVEMBER 2025 Source text: Further company coverage: ...